Difficulty: Medium
Average Score: 92%
Practice
A 58-year-old man presents to the emergency department (ED) after experiencing a sudden loss of motor control on his left side accompanied by aphasia. By the time he reached the ED, his symptoms had already resolved. He is given a prescription for a drug that binds platelet ADP receptors to prevent their aggregation. Which drug is this?
Correct answer
A
Rationale
In this scenario, the correct answer is A) Clopidogrel. Clopidogrel is an antiplatelet medication that works by binding to ADP receptors on platelets, thereby inhibiting platelet aggregation and reducing the risk of blood clot formation. This mechanism of action makes it effective in preventing thrombotic events like strokes, which can be caused by emboli originating from platelet-rich clots.
Option B) Enoxaparin is a low molecular weight heparin that acts by inhibiting factor Xa and factor IIa. While it is also used for its anticoagulant properties, it does not target platelet aggregation like Clopidogrel.
Option C) Eptifibatide and Option D) Tirofiban are both glycoprotein IIb/IIIa inhibitors that work by preventing the binding of fibrinogen to activated platelets, thus inhibiting platelet aggregation. However, these medications have a different mechanism of action compared to Clopidogrel and are typically used in acute coronary syndromes or during percutaneous coronary interventions.
In an educational context, understanding the mechanisms of action of different antiplatelet and anticoagulant medications is crucial for healthcare professionals, especially in emergency situations like the one described. This knowledge helps in selecting the most appropriate medication based on the clinical presentation and underlying pathology to provide optimal patient care and prevent future cardiovascular events.
Option B) Enoxaparin is a low molecular weight heparin that acts by inhibiting factor Xa and factor IIa. While it is also used for its anticoagulant properties, it does not target platelet aggregation like Clopidogrel.
Option C) Eptifibatide and Option D) Tirofiban are both glycoprotein IIb/IIIa inhibitors that work by preventing the binding of fibrinogen to activated platelets, thus inhibiting platelet aggregation. However, these medications have a different mechanism of action compared to Clopidogrel and are typically used in acute coronary syndromes or during percutaneous coronary interventions.
In an educational context, understanding the mechanisms of action of different antiplatelet and anticoagulant medications is crucial for healthcare professionals, especially in emergency situations like the one described. This knowledge helps in selecting the most appropriate medication based on the clinical presentation and underlying pathology to provide optimal patient care and prevent future cardiovascular events.